Oftan Tropicamid (Tropicamide)

Oftan Tropicamid, a mydriatic anticholinergic, is employed to achieve pupil dilation and cycloplegia in various ophthalmic settings.

• Diagnostic eye examinations: provides rapid and reliable pupil dilation to facilitate fundus evaluation and retinal imaging.
• Intraocular surgery preparation: creates sufficient mydriasis to improve surgical access and visualization during procedures such as cataract extraction.
• Cycloplegic testing: temporarily paralyzes the ciliary muscle, allowing accurate measurement of refractive errors and accommodation.

• Tropicamide acts as a selective antagonist of muscarinic acetylcholine receptors located in the iris sphincter and ciliary body muscles. By blocking these receptors, it prevents parasympathetic‑mediated contraction, leading to relaxation of the sphincter muscle (mydriasis) and inhibition of the ciliary muscle (cycloplegia). The effect appears within minutes and lasts for several hours, providing a controlled window for ocular examination or treatment.

Adverse reactions to Oftan Tropicamid are generally ocular but may include systemic manifestations.

Common Side Effects

• Transient blurred vision: temporary loss of visual clarity due to pupil dilation.
• Photophobia: increased sensitivity to light while the pupil remains enlarged.
• Ocular discomfort or mild burning sensation upon instillation.
• Mild headache or facial flushing.

Serious or Rare Side Effects

• Acute angle‑closure glaucoma: rapid rise in intra‑ocular pressure in susceptible eyes.
• Persistent mydriasis: prolonged pupil dilation lasting beyond the expected duration.
• Severe allergic reaction: swelling, rash, or anaphylaxis requiring immediate medical attention.
• Systemic anticholinergic effects: tachycardia, dry mouth, or urinary retention in rare cases.

Proper use of Oftan Tropicamid requires attention to patient history and handling to minimize risks.

• Assess intra‑ocular pressure before use: patients with narrow‑angle glaucoma are at increased risk of angle‑closure events.
• Avoid in individuals with known hypersensitivity to tropicamide or other anticholinergic agents.
• Use with caution in children and the elderly: systemic absorption may be higher.
• Monitor for signs of acute angle‑closure glaucoma after administration, especially in susceptible patients.
• Do not combine with other mydriatic agents unless directed by an ophthalmologist.
• Store at room temperature: keep in the original container, protect from light and moisture.

Tropicamide may interact with other medications that affect ocular physiology or systemic anticholinergic load.

Major Interactions (Avoid)

• Concurrent use with other potent anticholinergics (e.g., atropine) can lead to excessive systemic anticholinergic toxicity.
• Combination with adrenergic mydriatics such as phenylephrine may cause overly prolonged or intense pupil dilation.
• Use with drugs that significantly lower intra‑ocular pressure may mask pressure changes and delay detection of glaucoma.

Moderate Interactions (Monitor Closely)

• Systemic antihistamines or antidepressants with anticholinergic properties may increase ocular side effects.
• Topical beta‑blockers used for glaucoma may alter intra‑ocular pressure monitoring when tropicamide is administered.
• CYP450 inhibitors could theoretically raise systemic exposure, although ocular absorption is minimal; monitor for systemic signs.